<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autism spectrum disorder in children and adolescents: Complementary and alternative therapies</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autism spectrum disorder in children and adolescents: Complementary and alternative therapies</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autism spectrum disorder in children and adolescents: Complementary and alternative therapies</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Laura Weissman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Holly K Harris, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marilyn Augustyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autism spectrum disorder (ASD) is a biologically based neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction and restricted, repetitive patterns of behavior, interests, and activities.</p><p>The discussion that follows will focus on complementary and alternative therapies for ASD. Related topics are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/627.html" rel="external">"Autism spectrum disorder in children and adolescents: Clinical features"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/628.html" rel="external">"Autism spectrum disorder in children and adolescents: Evaluation and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/608.html" rel="external">"Autism spectrum disorder in children and adolescents: Overview of management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/603.html" rel="external">"Autism spectrum disorder in children and adolescents: Pharmacologic interventions"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/595.html" rel="external">"Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION OF CAM</span><span class="headingEndMark"> — </span>Complementary and alternative medicine (CAM) therapies, as defined by the National Center for Complementary and Alternative Medicine, are "a group of diverse medical and healthcare systems, practices, and products that are not generally considered to be part of conventional medicine" [<a href="#rid1">1</a>].</p><p>Alternative therapies are those that are used instead of conventional therapies. Complementary therapies are those that are used in conjunction with conventional therapies. The combination of conventional and complementary techniques that have some supportive evidence is often called "integrative medicine" [<a href="#rid2">2</a>]. Some of the interventions originally considered to be complementary may become part of conventional practice when there is scientific evidence to support their use. (See  <a class="medical medical_review" href="/d/html/2851.html" rel="external">"Complementary and integrative health in pediatrics", section on 'Definitions'</a>.)</p><p>Conventional therapies for ASD include behavioral therapies (eg, intensive behavioral therapy such as applied behavioral analysis). They have been shown to be effective in systematic reviews of randomized and observational studies and are discussed separately. (See  <a class="medical medical_review" href="/d/html/608.html" rel="external">"Autism spectrum disorder in children and adolescents: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions", section on 'Intensive behavioral interventions'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">PREVALENCE OF USE IN ASD</span><span class="headingEndMark"> — </span>Complementary and alternative medicine (CAM) is commonly used in children with special health care needs. In large studies of children with ASD, 27 to 88 percent of families report having used CAM therapies of any type, and 17 to 25 percent used special diets [<a href="#rid3">3-7</a>]. Rates tend to be higher in children with more severe forms of ASD, those diagnosed at an earlier age, those who are hyperactive or irritable, and those with gastrointestinal symptoms, food allergies, or seizures [<a href="#rid3">3,8</a>]. The types of therapies are diverse  (<a class="graphic graphic_table graphicRef81572" href="/d/graphic/81572.html" rel="external">table 1</a>). Vitamins, supplements, special diets, and body-based practices (eg, massage therapy, chiropractic) tend to be used most commonly [<a href="#rid2">2,5</a>].</p><p class="headingAnchor" id="H5"><span class="h1">RATIONALE FOR USE IN ASD</span><span class="headingEndMark"> — </span>ASD is a neurodevelopmental disorder with an incompletely understood etiology. Although core symptoms may improve over time with appropriate therapy, there is no known cure. Many caregivers of children with ASD seek both conventional and complementary and alternative (CAM) therapies as part of the process of understanding and accepting the diagnosis. (See  <a class="medical medical_review" href="/d/html/608.html" rel="external">"Autism spectrum disorder in children and adolescents: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/595.html" rel="external">"Autism spectrum disorder (ASD) in children and adolescents: Terminology, epidemiology, and pathogenesis", section on 'Pathogenesis'</a>.)</p><p>Some caregivers choose CAM due to perceived lack of efficacy of conventional treatments for ASD and in the hope of finding a cure, while others use CAM in addition to conventional treatments as they want to do everything possible to help their child [<a href="#rid2">2,9</a>]. Caregivers may choose CAM therapies to treat a variety of symptoms, including the core symptoms of ASD (eg, deficits in social communication and interaction and restricted, repetitive patterns of behavior, interests, and activities), inattention, gastrointestinal symptoms, and sleep disturbance; to promote a healthy lifestyle [<a href="#rid10">10</a>]; or out of concerns about safety or side effects of conventional allopathic therapies such as prescribed medications [<a href="#rid11">11</a>]. Some treatments are undertaken to address a biologic condition that the caregiver believes contributes to the pathogenesis of ASD, whether or not there is scientific evidence to support the hypothesis. Some of these biologic hypotheses propose that the development of ASD is related to [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Gastrointestinal abnormalities, such as dysbiosis (abnormalities of microflora) or "leaky gut," prompting the use of <a class="drug drug_pediatric" data-topicid="12784" href="/d/drug information/12784.html" rel="external">secretin</a>, antifungal agents, probiotics, etc (see <a class="local">'Secretin'</a> below and <a class="local">'Antimicrobial agents'</a> below and <a class="local">'Probiotics'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food sensitivities and allergies, prompting the use of special diets, such as the gluten-free and/or casein-free diet (see <a class="local">'Gluten-free casein-free diet'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmunity, prompting the use of immunotherapy (see <a class="local">'Intravenous immunoglobulin'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Metabolic abnormalities (eg, in glutathione synthesis, sulfation, folate metabolism), prompting the use of antioxidants [<a href="#rid13">13-15</a>] (see <a class="local">'Sulforaphane'</a> below and <a class="local">'Other interventions'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heavy metal toxicity, especially mercury, prompting the use of chelation therapy (see <a class="local">'Chelation'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional imbalances, prompting the use of nutritional supplements (eg, omega-3 fatty acids, vitamins) (see <a class="local">'Omega-3 fatty acids'</a> below and <a class="local">'Vitamin B6 and magnesium'</a> below and <a class="local">'Other interventions'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inflammation [<a href="#rid16">16</a>] (see <a class="local">'Sulforaphane'</a> below)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">CLINICIAN GUIDANCE</span></p><p class="headingAnchor" id="H8"><span class="h2">General principles</span><span class="headingEndMark"> — </span>Decisions about therapies for children with ASD should integrate clinical expertise, patient and caregiver values and preferences, and the best evidence of efficacy [<a href="#rid2">2,10,17-20</a>]. Although complementary and alternative (CAM) therapies are frequently used by families of children with ASD, few such therapies have been proven effective (or ineffective) or safe in controlled trials. Despite the lack of high-quality evidence, families use CAM, and certain CAM therapies are recommended by some clinicians [<a href="#rid21">21</a>].</p><p>It is important to ask caregivers of children with ASD specifically about the use of CAM therapies; they may not volunteer this information and may not realize that CAM therapies can have side effects and potential interactions with prescription medications [<a href="#rid5">5,6,22</a>]. General recommendations for counseling caregivers who choose CAM therapies for their children are provided separately  (<a class="graphic graphic_table graphicRef57149" href="/d/graphic/57149.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/2851.html" rel="external">"Complementary and integrative health in pediatrics", section on 'Discussing complementary therapies with patients and families'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Evaluation of evidence</span><span class="headingEndMark"> — </span>Clinicians should evaluate the evidence for all treatments, both conventional and CAM [<a href="#rid2">2,10</a>]. When evaluating the merits of a study, look for a homogeneous case definition, control for potential confounding variables, consistent dosing, appropriate comparison group, appropriate blinding (if applicable), valid outcome measure(s), and adequate sample size [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/2763.html" rel="external">"Evidence-based medicine"</a>.)</p><p>The natural history of ASD, effects of other interventions (eg, conventional educational or behavioral interventions), and the placebo effect also must be taken into account [<a href="#rid23">23-25</a>]. Patients with chronic conditions with unclear pathophysiology, fluctuating courses, subjective symptoms, and few effective evidence-based treatments (such as ASD) are most vulnerable to the placebo effect.</p><p>In the hierarchy of evidence, randomized, blinded, placebo-controlled studies provide the highest-quality evidence. However, it is often difficult to perform such studies in children with ASD. Thus, much of the evidence for both conventional and CAM therapies comes from cohort studies, case-control studies, and case reports. Choosing an appropriate outcome measure is another challenge in the evaluation of interventions for ASD given the heterogeneity of presentations within the autism spectrum. Instruments that are typically used for diagnosis may not demonstrate incremental improvements in core deficits.</p><p class="headingAnchor" id="H10"><span class="h2">Potential harms</span><span class="headingEndMark"> — </span>CAM therapies may compete with validated treatments for time, effort, and financial resources. There are few data about the adverse effects of CAM therapies. The magnitude of risk for hypersensitivity, systemic toxicity, and/or topical toxicity is not known. Nutritional supplements (eg, omega-3 fatty acids, <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">vitamin B6</a>, magnesium) are classified as foods rather than drugs. As such, they are subject to different regulations and quality controls. The potential presence of contaminants and interactions of these supplements with prescription drugs have not been studied systematically.</p><p class="headingAnchor" id="H11"><span class="h2">Counseling caregivers</span><span class="headingEndMark"> — </span>Medical practitioners play an essential role in helping caregivers evaluate information regarding CAM for children with ASD. Although caregivers of children with ASD may seek CAM therapies, they also value the recommendations of their health care providers [<a href="#rid11">11</a>]. However, patients/caregivers often do not disclose the use of CAM to clinicians, so it is important that clinicians ask specifically about CAM therapies. (See  <a class="medical medical_review" href="/d/html/2851.html" rel="external">"Complementary and integrative health in pediatrics", section on 'Relationship between integrative and mainstream medicine'</a>.)</p><p>It is important for clinicians who care for children with ASD to know about CAM therapies and provide balanced information and advice about the potential benefits and risks [<a href="#rid26">26</a>]. Many caregivers use more than one treatment [<a href="#rid27">27</a>]. When counseling caregivers who are considering the use of CAM therapies that lack supportive data, the importance of using only one new therapy at a time and collecting objective outcome data should be emphasized.</p><p class="headingAnchor" id="H2049798475"><span class="h2">Healthy lifestyle</span><span class="headingEndMark"> — </span>A healthy lifestyle is encouraged for children with ASD, as for all children. This includes a healthy diet (including adequate intake of essential nutrients), regular exercise, adequate sleep, management of stress, social support, and avoidance of neurotoxins [<a href="#rid10">10</a>]. In a randomized crossover study, a seven-week aerobic cycling program (using virtual-reality exergaming stationary bicycles) was associated with improved self-regulation and classroom functioning in 103 children with behavioral health disorders (including approximately 40 percent with ASD) [<a href="#rid28">28</a>].</p><p>Vitamin D supplementation to meet daily requirements may be necessary in children with inadequate intake of vitamin D [<a href="#rid29">29</a>]. However, evidence that vitamin D supplementation improves the core symptoms of ASD is lacking [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children"</a> and  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a> and <a class="local">'Unknown benefit, low risk'</a> below.)</p><p class="headingAnchor" id="H3310263980"><span class="h1">CLASSIFICATION ACCORDING TO BENEFITS AND RISKS</span><span class="headingEndMark"> — </span>Evaluation of complementary and alternative (CAM) interventions for the core symptoms of ASD is an active area of investigation. However, few CAM therapies have been proven effective/ineffective or safe as part of well-designed randomized controlled trials (eg, adequate sample size and blinding, use of appropriate validated outcome measures, adequate duration). Given the uncertainty, the clinician and caregivers must weigh the potential benefits and risks, including competition with validated treatment for time, effort, and financial resources. (See <a class="local">'Potential harms'</a> above.)</p><p>Our recommendations are generally consistent with those of the American Academy of Pediatrics [<a href="#rid26">26</a>], National Institute of Health and Care Excellence [<a href="#rid31">31</a>], the Scottish Intercollegiate Guidelines [<a href="#rid32">32</a>], and the Technical Expert Panel (a large multidisciplinary group consisting of experts in psychology, developmental pediatrics, child psychiatry, and education, and parents of children with autism) [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H4147455695"><span class="h2">No benefit</span></p><p class="headingAnchor" id="H1152028373"><span class="h3">Secretin</span><span class="headingEndMark"> — </span>We do not recommend <a class="drug drug_pediatric" data-topicid="12784" href="/d/drug information/12784.html" rel="external">secretin</a> for children with ASD. It does not improve core features of ASD [<a href="#rid34">34</a>].</p><p><a class="drug drug_pediatric" data-topicid="12784" href="/d/drug information/12784.html" rel="external">Secretin</a> is a gastrointestinal hormone. It inhibits intestinal motility and release of gastric acid and stimulates secretion of pancreatic fluid and bicarbonate. The use of secretin as a potential therapy for children with ASD is based upon the hypothesis that autism is related to gastrointestinal abnormalities [<a href="#rid35">35</a>]. However, there is little evidence to support this hypothesis [<a href="#rid36">36</a>]. A 2012 systematic review that included 16 randomized controlled trials involving &gt;900 children found no evidence that secretin improves the core features of autism [<a href="#rid34">34</a>]. No serious side effects were reported. (See  <a class="medical medical_review" href="/d/html/603.html" rel="external">"Autism spectrum disorder in children and adolescents: Pharmacologic interventions", section on 'Gastrointestinal problems'</a>.)</p><p class="headingAnchor" id="H386231422"><span class="h3">Facilitated communication</span><span class="headingEndMark"> — </span>We do not recommend facilitated communication as a means of communicating with children with ASD.</p><p>Facilitated communication is a technique in which a facilitator physically guides the hand of a nonverbal child in using an output device (eg, keyboard, mouse) for communication [<a href="#rid37">37</a>]. Reviews of published studies of facilitated communication found no evidence to support its use for individuals with communication impairment [<a href="#rid32">32,38</a>]. Controlled studies revealed that the facilitator, rather than the child, was providing information [<a href="#rid39">39</a>].</p><p>Facilitated communication must be distinguished from augmentative communication, an established method of nonverbal communication in which manual sign, picture exchange, switches, or voice output devices are used without the aid of a facilitator. Augmentative communication is an appropriate intervention in some children with ASD and is discussed separately. (See  <a class="medical medical_review" href="/d/html/607.html" rel="external">"Autism spectrum disorder in children and adolescents: Behavioral and educational interventions", section on 'Communication interventions'</a>.)</p><p class="headingAnchor" id="H4160172429"><span class="h2">Possible benefit, potential risk</span></p><p class="headingAnchor" id="H3107293421"><span class="h3">Gluten-free casein-free diet</span><span class="headingEndMark"> — </span>We do not suggest a gluten-free casein-free (GFCF) diet for children with ASD unless there is evidence of celiac disease or true gluten sensitivity. Evidence of efficacy is limited and weak [<a href="#rid40">40</a>]; strict adherence to the diet is difficult and may be associated with nutritional deficiencies (eg, calcium, vitamin D, amino acids) unless monitored by a registered dietician [<a href="#rid41">41</a>].</p><p>Despite the lack of evidence, many caregivers choose to follow a GFCF diet for their child with ASD. We counsel such caregivers about the need for adequate vitamin D, calcium, and protein intake. Rice milk, almond milk, and potato milk are not sufficient sources of protein. (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children"</a>.)</p><p>The use of the GFCF diet for children with ASD is based upon the hypothesis that increased gut permeability allows gluten and casein peptides to leak from the gut, causing excessive opioid activity and resulting in behaviors observed in ASD [<a href="#rid12">12</a>]. However, children with ASD have neither increased rates of celiac disease nor excessive amounts of opioid-like compounds in their urine [<a href="#rid23">23,42-45</a>].</p><p>Systematic reviews of randomized trials evaluating the GFCF diet in children with ASD have concluded that the evidence of benefit is limited and weak [<a href="#rid40">40,41,46,47</a>]. Limitations include lack of blinding, small sample size, and differences in patient population, interventions, and outcome measures.</p><p>In a meta-analysis of six randomized trials (143 participants), clinician-reported ASD core symptoms, caregiver-reported functional level, and behavioral difficulties were similar in children assigned to a GFCF diet or a regular diet [<a href="#rid47">47</a>]. The quality of the evidence is limited by inconsistency, imprecision, and risk of bias. In a subsequent randomized trial in 66 children (ages 36 to 69 months), no differences in autism symptoms, maladaptive behaviors, or intellectual abilities were detected after six weeks of the study diet [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H1265344152"><span class="h2">Unknown benefit, potential risk</span><span class="headingEndMark"> — </span>The therapies described in this section have little evidence of efficacy and are potentially harmful. Their use may compete with validated therapies for time, effort, and financial resources. Given the potential harms, we discourage their use in the treatment of ASD.</p><p class="headingAnchor" id="H3738721609"><span class="h3">Intravenous immunoglobulin</span><span class="headingEndMark"> — </span>We do not recommend intravenous immunoglobulin (<a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">IVIG</a>) for the treatment of ASD in the absence of other indications for IVIG (eg, documented immune deficiency). (See  <a class="medical medical_review" href="/d/html/3911.html" rel="external">"Immune globulin therapy in inborn errors of immunity", section on 'Indications'</a>.)</p><p>The use of <a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">IVIG</a> and other immune therapies for children with ASD is based on the hypothesis that ASD is related to dysregulation in the immune system [<a href="#rid9">9,49</a>]. The data underlying this hypothesis are limited [<a href="#rid50">50,51</a>]. Although small open-label trials of IVIG in children with ASD suggest improvement in some domains [<a href="#rid52">52-54</a>], the evidence is inconsistent [<a href="#rid55">55,56</a>], and adverse effects were common. In the only blinded, placebo-controlled randomized trial in 12 males with ASD, clinician ratings were similar in the IVIG and placebo groups, although there was greater improvement from baseline scores on some subscales of the Aberrant Behavior Checklist (ABC) or symptoms checklists [<a href="#rid57">57</a>]; the authors of the study noted that the benefits of IVIG may be limited to selected patients and cautioned against indiscriminate use. </p><p><a class="drug drug_pediatric" data-topicid="83878" href="/d/drug information/83878.html" rel="external">IVIG</a> is expensive. Potential adverse effects of IVIG and other immune therapies include transmission of bloodborne pathogens. (See  <a class="medical medical_review" href="/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Infectious risks'</a>.)</p><p class="headingAnchor" id="H3510782975"><span class="h3">Chelation</span><span class="headingEndMark"> — </span>We strongly discourage the use of chelation for the treatment of ASD. There is no evidence of efficacy and potential for serious harm.</p><p>Chelation is a process of administering a substance (such as ethylene diamine tetra-acetic acid [EDTA], 2,3-dimercaptosuccinic acid [DMSA], or 2,3-dimercaptopropane-1-sulfonate [DMPS]), to remove heavy metals from the body.</p><p>The use of chelation for ASD is based upon the hypothesis that the behaviors observed in children with ASD are secondary to toxicity from mercury or other heavy metals and that children with ASD do not excrete heavy metals effectively. However, there is little evidence to support this hypothesis [<a href="#rid58">58</a>]. The clinical manifestations of mercury toxicity do not resemble those of ASD, and evidence to support a causal relationship between thimerosal and autism is lacking. (See  <a class="medical medical_review" href="/d/html/7179.html" rel="external">"Mercury toxicity", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/2861.html" rel="external">"Autism spectrum disorder and chronic disease: No evidence for vaccines or thimerosal as a contributing factor"</a>.)</p><p>The safety and efficacy of chelation therapy for ASD, including nonprescription oral or rectal products, has not been well studied in controlled trials [<a href="#rid59">59,60</a>]. The only randomized trial [<a href="#rid61">61,62</a>] had methodologic limitations [<a href="#rid63">63</a>]. Chelation agents bind ions nonspecifically and may result in decreased levels of calcium, iron, and magnesium as well as toxic heavy metals. When used for documented heavy metal poisoning, chelation requires close monitoring. Death due to hypocalcemia has been reported when sodium EDTA rather than calcium EDTA was used for chelation [<a href="#rid64">64,65</a>].</p><p class="headingAnchor" id="H1935931242"><span class="h3">Hyperbaric oxygen</span><span class="headingEndMark"> — </span>We do not recommend hyperbaric oxygen therapy (HBOT) as a treatment for ASD. It is costly and there is insufficient information about its efficacy.</p><p>The use of HBOT to treat autism is based upon the hypothesis that increasing atmospheric pressure enhances oxygen delivery to the brain to reduce swelling and promote brain recovery [<a href="#rid66">66</a>].</p><p>A 2016 systematic review [<a href="#rid67">67</a>] included only one randomized trial in 60 children, in which HBOT did not improve social interaction, behavioral problems, communication, or cognitive function in children with ASD. A subsequent review of the literature from 2015 to 2021 concluded that the effectiveness of HBOT for children with ASD is unconfirmed [<a href="#rid68">68</a>]. Adverse effects of HBOT include barotrauma to the middle ear, sinuses, or lungs; reversible myopia; pulmonary oxygen toxicity; and seizures. (See  <a class="medical medical_review" href="/d/html/326.html" rel="external">"Hyperbaric oxygen therapy", section on 'Complications'</a>.)</p><p class="headingAnchor" id="H4190929576"><span class="h3">Antimicrobial agents</span><span class="headingEndMark"> — </span>We do not recommend antimicrobial agents (eg, antifungal agents [eg, <a class="drug drug_pediatric" data-topicid="12654" href="/d/drug information/12654.html" rel="external">nystatin</a>, <a class="drug drug_pediatric" data-topicid="13303" href="/d/drug information/13303.html" rel="external">fluconazole</a>], antibiotics, or antiviral agents) in the treatment of ASD. They have unproven efficacy and potential adverse effects.</p><p>The use of antimicrobial agents is based upon the hypothesis that individuals with ASD have an imbalance of intestinal microbes (eg, overgrowth of yeast or bacteria) [<a href="#rid2">2,69</a>].</p><p>Few controlled trials have evaluated antimicrobial therapies in children with ASD [<a href="#rid2">2,70</a>]. Adverse effects include hypersensitivity reaction, hepatotoxicity, anemia, diarrhea, exfoliative dermatitis, and promotion of antimicrobial resistance [<a href="#rid23">23,37</a>].</p><p class="headingAnchor" id="H209465574"><span class="h3">Vitamin B6 and magnesium</span><span class="headingEndMark"> — </span>We do not recommend <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">vitamin B6</a> (pyridoxine) and magnesium supplementation for the treatment of ASD.</p><p>Although there is a long history of treatment of mental health disorders with <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">vitamin B6</a> and magnesium (which was added to reduce the side effects of vitamin B6), few high-quality studies have specifically evaluated B6-magnesium supplementation for ASD [<a href="#rid9">9,71</a>]. A 2010 systematic review of three small and methodologically flawed randomized trials (total of 33 patients) found the evidence inconclusive [<a href="#rid72">72</a>].</p><p>Megadoses of <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">vitamin B6</a> (&gt;100 mg/day) may result in neuropathy. (See  <a class="medical medical_review" href="/d/html/5367.html" rel="external">"Overview of water-soluble vitamins", section on 'Vitamin B6 (pyridoxine)'</a>.)</p><p class="headingAnchor" id="H3635356543"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Other interventions with unproven benefit for ASD and potential adverse effects include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin A; adverse effects of vitamin A are discussed separately. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A", section on 'Excess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin D supplementation outside of vitamin D deficiency, and in excess of daily requirements and tolerable upper intake level  (<a class="graphic graphic_table graphicRef81151" href="/d/graphic/81151.html" rel="external">table 3</a>); in a small randomized trial, vitamin D supplementation did not improve the core symptoms of ASD [<a href="#rid30">30</a>]. Adverse effects of excess vitamin D are discussed separately. (See  <a class="medical medical_review" href="/d/html/2033.html" rel="external">"Overview of vitamin D", section on 'Excess'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Homeopathic remedies (may contain unlabeled toxic ingredients [<a href="#rid73">73</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vagus nerve stimulation is an accepted intervention for the management of epilepsy; its effectiveness for ASD is unproven. Adverse effects of vagus nerve stimulation therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/2229.html" rel="external">"Vagus nerve stimulation therapy for the treatment of epilepsy", section on 'Side effects and complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stem cell transplantation is being investigated as a treatment for some central nervous system disorders requiring neural regeneration (eg, spinal cord injury) [<a href="#rid74">74</a>]. However, given that ASD is a neurodevelopmental disorder of neural connectivity, regenerative treatment with stem cells does not make sense physiologically [<a href="#rid75">75</a>]. It is potentially harmful [<a href="#rid76">76,77</a>], as well as expensive.</p><p></p><p>Given the lack of proven benefit and potential harms, we do not recommend these therapies for our patients with ASD.</p><p class="headingAnchor" id="H2530826102"><span class="h2">Possible benefit, low risk</span><span class="headingEndMark"> — </span>The therapies described in this section have possible benefit and low risk. Given the unestablished benefits, with the exception of melatonin for sleep disturbance, we do not actively encourage their use for the management of ASD. However, we do not discourage caregivers from using them if they choose to do so. In that case, we monitor for side effects, interactions, and effects on prescribed/recommended therapy.</p><p class="headingAnchor" id="H3482098350"><span class="h3">Music therapy</span><span class="headingEndMark"> — </span>Music therapy may be beneficial for children with ASD and is unlikely to be harmful [<a href="#rid2">2,78-80</a>]. Pending additional studies, we do not actively encourage using music therapy to manage core features of ASD unless it is a component of a broader comprehensive behavior program. (See  <a class="medical medical_review" href="/d/html/608.html" rel="external">"Autism spectrum disorder in children and adolescents: Overview of management", section on 'Behavioral and educational interventions'</a>.)</p><p>The use of music therapy for children with ASD is based upon the hypothesis that engaging in musical interaction (sometimes understood to be a kind of nonverbal or preverbal language) may facilitate the development of communication skills and capacity for social interaction [<a href="#rid80">80</a>].</p><p>A systematic review of 26 clinical trials (1165 participants) that compared music therapy with standard care or "placebo" therapy (similar treatment without music) concluded with moderate certainty that immediately after the intervention, music therapy probably results in global improvement, likely improves total autism severity and quality of life, and probably does not increase adverse events [<a href="#rid80">80</a>]. Whether music therapy improves social interaction, nonverbal communication, and verbal communication remains uncertain. Although differences between groups were not detected, the certainty of the evidence was low (due to risk of bias and imprecision).</p><p class="headingAnchor" id="H371813400"><span class="h3">Melatonin</span><span class="headingEndMark"> — </span>The use of melatonin for sleep disturbance in children with ASD is discussed separately. (See  <a class="medical medical_review" href="/d/html/603.html" rel="external">"Autism spectrum disorder in children and adolescents: Pharmacologic interventions", section on 'Sleep disturbance'</a>.)</p><p class="headingAnchor" id="H3820813518"><span class="h3">Oxytocin</span><span class="headingEndMark"> — </span>The use of oxytocin in children with ASD is discussed separately. (See  <a class="medical medical_review" href="/d/html/603.html" rel="external">"Autism spectrum disorder in children and adolescents: Pharmacologic interventions", section on 'Investigative therapies for social deficits'</a>.)</p><p class="headingAnchor" id="H1465470578"><span class="h3">Therapeutic horseback riding</span><span class="headingEndMark"> — </span>We do not actively encourage therapeutic horseback riding (hippotherapy) as a core treatment for children with ASD, but it is not discouraged if monitored appropriately in the context of a broader comprehensive behavioral/educational program. Although there is some evidence of benefit [<a href="#rid81">81-85</a>], additional studies are necessary before it can be actively recommended [<a href="#rid2">2</a>].</p><p>Therapeutic horseback riding is hypothesized to stimulate multiple domains of functioning (eg, cognitive, social, gross motor) in children with ASD [<a href="#rid81">81</a>]. In a randomized trial that compared 10 weeks of therapeutic horseback riding with 10 weeks of a barn activity not involving horses in 116 children and adolescents with ASD, therapeutic horseback riding improved measures of irritability and hyperactivity after approximately five weeks [<a href="#rid82">82</a>]. Therapeutic horseback riding also improved social cognition and social communication as assessed by parent report. In a smaller nonrandomized study, 19 children with autism who participated in 12 weeks of therapeutic horseback riding demonstrated improvements in attention, distractibility, and social motivation compared with 15 waitlist controls [<a href="#rid81">81</a>].</p><p>Therapeutic horseback riding is associated with a risk of injury similar to that in other "limited contact" recreational activities (eg, baseball, skating). When discussing horseback riding with caregivers who choose to participate, it is important to emphasize the need to wear a helmet and for appropriate supervision [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H1012415454"><span class="h3">Other types of animal/pet therapy</span><span class="headingEndMark"> — </span>Observational studies suggest that the presence of animals may reduce social stress and increase social behaviors in patients with ASD [<a href="#rid86">86,87</a>], but additional studies are necessary before animal therapy can be recommended [<a href="#rid88">88</a>].</p><p>A pilot randomized trial that compared canine-assisted occupational therapy with standard occupational therapy (waitlist control) in 22 children with ASD found a trend toward improved on-task behavior and goal attainment with canine-assisted occupational therapy, but additional study is necessary [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H166609035"><span class="h3">Sulforaphane</span><span class="headingEndMark"> — </span>We do not encourage sulforaphane supplementation for children with ASD. Additional studies documenting benefit are necessary.</p><p>Sulforaphane is an antioxidant derived from broccoli sprout extracts that increases the activity of genes that protect aerobic cells against oxidative stress, inflammation, and deoxyribonucleic acid (DNA) damage [<a href="#rid90">90,91</a>]. It is hypothesized to reverse abnormalities associated with ASD including neuroinflammation; oxidative stress; and decreased glutathione synthesis, mitochondrial function, and oxidative phosphorylation.</p><p>The effects of sulforaphane on ASD were evaluated in a trial in which young men (age 13 to 27 years) were randomly assigned to receive 18 weeks of daily sulforaphane (n = 29) or placebo (n = 15) [<a href="#rid92">92</a>]. During treatment, sulforaphane recipients had improved behavior compared with baseline as assessed by parents and clinicians on the ABC, Social Responsiveness Scale, and Clinical Global Impression Improvement Scale. When sulforaphane was discontinued, behavior returned to baseline. In a subsequent placebo-controlled, randomized trial in 57 children (age 3 to 12 years) with ASD, 45 were available for follow-up after 15 weeks (22 in the sulforaphane group and 23 in the placebo group) [<a href="#rid93">93</a>]. Clinical effects varied with outcome measure (no benefit detected on the Ohio Autism Clinical Impressions Scale or the Social Responsiveness Scale, Second Edition; improvement on the ABC) and were less notable than the trial in young men [<a href="#rid93">93</a>]. Sulforaphane appeared to be well-tolerated in both trials, but the trials were too small to adequately assess adverse effects. Although these results are promising, additional information is needed.</p><p>Pending additional study, we do not specifically recommend that children with ASD eat broccoli sprouts or other sulforaphane-rich foods (eg, brussel sprouts, broccoli), but eating these vegetables is not discouraged given the other health benefits of these foods. Study participants received 50 to 150 micromol of sulforaphane, much more than can be obtained from food [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H2917575028"><span class="h3">Transcranial magnetic stimulation</span><span class="headingEndMark"> — </span>We do not recommend transcranial magnetic stimulation (TMS) for children with ASD, except as part of a clinical trial. Although it appears to be safe in the context of clinical trials, additional study is necessary before TMS can be recommended for treatment of ASD in children [<a href="#rid2">2,95</a>].</p><p>TMS is an energy-based therapy that is proposed to work through electromagnetic induction, which modifies neuroexcitability. Controlled and uncontrolled studies have demonstrated potential benefit in patients with depression, bipolar illness, schizophrenia, epilepsy, and Tourette syndrome. (See  <a class="medical medical_review" href="/d/html/2214.html" rel="external">"Evaluation and management of drug-resistant epilepsy", section on 'Other stimulation approaches'</a> and  <a class="medical medical_review" href="/d/html/14641.html" rel="external">"Unipolar depression in adults: Indications, efficacy, and safety of transcranial magnetic stimulation (TMS)"</a>.)</p><p>The use of TMS for children with ASD is based upon the hypothesis that autism is related to a disturbance of cortical modularity [<a href="#rid96">96</a>]. A 2016 literature review found some evidence that TMS may reduce symptoms of ASD (core symptoms and associated symptoms), but more rigorous study is necessary [<a href="#rid95">95</a>]. TMS is generally considered safe in children and adults [<a href="#rid97">97,98</a>]. Seizures, the most serious TMS adverse event, are extremely rare [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H3635802162"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Other interventions that lack definitive scientific evidence of a benefit but are unlikely to be harmful for children with ASD include [<a href="#rid2">2,78,100</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Yoga [<a href="#rid101">101-103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Body work and energy therapies (eg, qigong massage, therapeutic touch, healing touch, Reiki) [<a href="#rid79">79,103-106</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biofeedback/neurofeedback [<a href="#rid107">107,108</a>] – In biofeedback/neurofeedback, behavioral therapy is focused on achieving self-regulation of cortical electrical activity as measured by electroencephalogram, often using visual feedback. Reported side effects are minimal but can include headache. Although neurofeedback is safe, it may be expensive [<a href="#rid10">10</a>], and benefits remain unproven for the core symptoms of ASD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypnotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12806" href="/d/drug information/12806.html" rel="external">Vitamin C</a> (doses up to 2 g/day [<a href="#rid10">10</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13187" href="/d/drug information/13187.html" rel="external">Vitamin B12</a> [<a href="#rid40">40,109,110</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Folinic acid [<a href="#rid111">111,112</a>] and <a class="drug drug_pediatric" data-topicid="13322" href="/d/drug information/13322.html" rel="external">folic acid</a> [<a href="#rid113">113</a>].</p><p></p><p>Given the lack of definitive evidence of benefit, we do not encourage these interventions for our patients with ASD.</p><p class="headingAnchor" id="H1899787808"><span class="h2">Unknown benefit, low risk</span><span class="headingEndMark"> — </span>The therapies described in this section have unknown benefit but low risk. Given the unknown benefits, we do not encourage them for the management of ASD. If caregivers choose to use them, we monitor for side effects, interactions, and effects on prescribed/recommended therapy.</p><p class="headingAnchor" id="H712545549"><span class="h3">Auditory integration training</span><span class="headingEndMark"> — </span>We do not encourage using auditory integration training (AIT) for children with ASD. Although the risk of adverse effects is low, the efficacy is unproven and it is expensive [<a href="#rid2">2,79</a>].</p><p>The use of AIT in children with ASD is based upon the hypothesis that repeated exposure to altered sound via headphones functionally modifies central auditory processing, impacting language and behavior.</p><p>Systematic reviews of randomized trials have concluded that auditory integration therapy does not improve language outcomes in children with ASD [<a href="#rid33">33,79,114</a>]. The evidence is limited by inconsistency and small sample size.</p><p class="headingAnchor" id="H1264568700"><span class="h3">Omega-3 fatty acids</span><span class="headingEndMark"> — </span>Although there might be some benefits, we do not advise use of omega-3 fatty acids as a therapy for the core symptoms of ASD. Omega-3 fatty acids (eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) are essential fatty acids with potential cardiovascular benefits. Some studies suggest that plasma omega-3 concentrations in children with ASD are decreased, but no clear clinical correlation has been established [<a href="#rid115">115-117</a>].</p><p>Systematic reviews of randomized trials evaluating omega-3 fatty acids for ASD have had inconsistent findings [<a href="#rid40">40,118-121</a>]. Most have concluded that omega-3 fatty acid supplementation does not improve core symptoms of ASD or symptoms associated with ASD, but is not likely to be harmful [<a href="#rid40">40,118-120</a>]. Although a meta-analysis concluded that omega-3 supplementation had small beneficial effects on language, social deficits, and associated symptoms (eg, inattention, irritability, behavioral difficulties, cognition) [<a href="#rid121">121</a>], the findings are limited by the quality of the included studies [<a href="#rid122">122</a>].</p><p>The American Heart Association suggests two servings of fish per week for the cardiovascular benefit. (See  <a class="medical medical_review" href="/d/html/2866.html" rel="external">"Dietary recommendations for toddlers and preschool and school-age children", section on 'Meat and protein'</a>.)</p><p>Common side effects of omega-3 supplementation include gastrointestinal distress (eg, nausea, diarrhea). No major side effects were reported in the studies of omega-3 supplementation for ASD [<a href="#rid118">118,119,123,124</a>]. Omega-3 fatty acid supplementation should be used with caution in patients with bleeding disorders or sensitivity to fish.</p><p>No specific dosing guidelines for omega-3 fatty acids are available. Studies in children with ASD used 1.3 and 1.5 g/day [<a href="#rid123">123,124</a>].</p><p>Omega-3 fatty acid supplementation for children with developmental coordination disorder and attention deficit hyperactivity disorder is discussed separately. (See  <a class="medical medical_review" href="/d/html/89809.html" rel="external">"Developmental coordination disorder: Management and outcome", section on 'Fatty acid supplementation'</a> and  <a class="medical medical_review" href="/d/html/623.html" rel="external">"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis", section on 'Essential fatty acid supplementation'</a>.)</p><p class="headingAnchor" id="H2890212904"><span class="h3">Probiotics</span><span class="headingEndMark"> — </span>Probiotics are hypothesized to address an imbalance of intestinal microbes in individuals with ASD. US Food and Drug Administration regulation of probiotics depends upon how they are categorized (eg, biologic product, drug, dietary supplement, medical food, food ingredient [<a href="#rid125">125</a>]). Those that are less stringently regulated may contain unlabeled ingredients or species [<a href="#rid126">126</a>].</p><p>Although there continues to be great interest and ongoing research into the relationship between the gut microbiome and ASD, there is not enough evidence to determine if there is a causal relationship and, if so, to understand the direction of this relationship (eg, there is suggestion that the restricted diet of many individuals with ASD impacts the gut microbiome [<a href="#rid127">127</a>] rather than the microbiome causing the symptoms of ASD).</p><p>We do not encourage probiotics for the management of ASD. Although they are unlikely to be harmful, they have not been rigorously studied in children with ASD. A systematic review that included six clinical trials concluded that probiotics have limited efficacy in the management of gastrointestinal or behavioral symptoms in children with ASD [<a href="#rid128">128</a>]. The included studies used different strains, concentrations, and duration of probiotics. There is some evidence to suggest that probiotics may be beneficial for other conditions (eg, acute gastroenteritis, functional abdominal pain). (See  <a class="medical medical_review" href="/d/html/5992.html" rel="external">"Acute viral gastroenteritis in children in resource-abundant countries: Management and prevention", section on 'Probiotics and prebiotics'</a> and  <a class="medical medical_review" href="/d/html/112.html" rel="external">"Functional abdominal pain in children and adolescents: Management in primary care", section on 'Management of symptoms'</a>.)</p><p class="headingAnchor" id="H1965310043"><span class="h3">Cannabinoids</span><span class="headingEndMark"> — </span>We do not encourage medical marijuana or cannabinoids for the treatment of ASD or related symptoms. Cannabinoids include cannabidiol (CBD, the nonpsychoactive component of marijuana), tetrahydrocannabinol (THC, the psychoactive component), and <a class="drug drug_pediatric" data-topicid="13256" href="/d/drug information/13256.html" rel="external">dronabinol</a> (synthetic THC), among others. Although CBD is available for the treatment of certain types of epilepsy in children and appears to be safe, the benefits for children with ASD are uncertain [<a href="#rid129">129,130</a>]. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a> and  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Cannabidiol'</a>.)</p><p>Although an animal model suggests that endocannabinoid signaling pathways may play a role in genetic disorders related to ASD (eg, fragile X syndrome) [<a href="#rid131">131</a>], research evaluating the direct effects of <a class="drug drug_general" data-topicid="134930" href="/d/drug information/134930.html" rel="external">medical cannabis</a> in individuals with ASD is limited. In a randomized trial in 150 participants (age 5 to 21 years) with ASD, efficacy of benefit was inconsistent [<a href="#rid132">132</a>]. The study was limited by a lack of pharmacokinetic data and a wide range of subject ages and functional levels. Additional randomized and open trials of the effects of cannabinoids on the behavior of children with ASD are underway [<a href="#rid133">133-135</a>]. Observational studies report subjective improvements in behavioral problems (self-injury, hyperactivity), anxiety, and sleep, along with reduced need for other psychoactive medications [<a href="#rid136">136-140</a>]. Limitations include lack of objective assessment tools, poor follow-up, attrition, and lack of uniform cannabinoid dosing.</p><p>In randomized trials and observational studies of cannabinoids in patients with ASD, adverse effects included somnolence, decreased appetite, irritability, and restlessness [<a href="#rid132">132,136-140</a>]. In randomized trials of CBD in children with Lennox-Gastaut syndrome and Dravet syndrome, adverse effects included somnolence, fever, decreased appetite, diarrhea, and vomiting [<a href="#rid141">141-143</a>]. However, some children discontinued CBD because of elevation of liver aminotransferase concentrations. (See  <a class="medical medical_review" href="/d/html/138854.html" rel="external">"Lennox-Gastaut syndrome"</a> and  <a class="medical medical_review" href="/d/html/108722.html" rel="external">"Dravet syndrome: Management and prognosis", section on 'Cannabidiol'</a>.)</p><p>Additional information about the medical use of marijuana is provided separately. (See  <a class="medical medical_review" href="/d/html/7797.html" rel="external">"Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects", section on 'Medico-legal context'</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Other interventions</span><span class="headingEndMark"> — </span>Other interventions with unknown benefit but low risk of harm include [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Methylcobalamin and <a class="drug drug_pediatric" data-topicid="13239" href="/d/drug information/13239.html" rel="external">N-acetylcysteine</a> [<a href="#rid14">14,144-146</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Zinc.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Herbal products.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amino acids, which include dimethylglycine (DMG, a derivative of glycine) as well as others (eg, taurine, lysine, gamma-aminobutyric acid [GABA]) [<a href="#rid147">147,148</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Digestive enzymes [<a href="#rid40">40,149,150</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mindfulness therapy has been studied in parents of children with ASD and in children with ASD [<a href="#rid151">151-156</a>], but the quality of the evidence is low due to methodologic limitations (eg, small sample size, self-reported outcome measures, ) [<a href="#rid103">103,157</a>]; mindfulness therapy is unlikely to be harmful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acupuncture – Although generally considered to be safe [<a href="#rid158">158-160</a>], there is a risk of injury in uncooperative patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Craniosacral manipulation – Although systematic reviews suggest that craniosacral manipulation is low risk [<a href="#rid2">2</a>], adverse effects may be underreported [<a href="#rid161">161</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chiropractic (generally safe for children without spinal abnormalities).</p><p></p><p class="headingAnchor" id="H32"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>For pediatric health care providers seeking more information about complementary and alternative (CAM) therapies or current trials of CAM therapies in children with ASD, the following websites might be useful [<a href="#rid162">162</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2F&amp;token=nbsXe3i4qfUea5RCPRHtOc5ko1zksgMm05jF47%2FUSB3l0tvt%2BGAm3dUe1JoUg9nw&amp;TOPIC_ID=605" target="_blank">ClinicalTrials.gov</a> – The clinical trials registry of federally and privately supported clinical trials</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.nccih.nih.gov%2Fhealth%2Fautism&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fz3wh0Bqb8lzeSfvlLTqiX5uuvOpCOL7EVxkxq0IWzAw&amp;TOPIC_ID=605" target="_blank">National Center for Complementary and Integrative Health</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fasatonline.org%2F&amp;token=c9ulPw%2BAgmvW5eqPGsXtUNFuakE3%2F76Age%2F39h1k5D8%3D&amp;TOPIC_ID=605" target="_blank">Association for Science in Autism Treatment</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.autism-society.org%2F&amp;token=0e64WmB8Y%2B9YkspAK0sxMK1BeZkLoCkLMdGKhCuKOZ9n7KTWZlQiQEjERt5SQjqK&amp;TOPIC_ID=605" target="_blank">Autism Society of America</a></p><p></p><p class="headingAnchor" id="H2784983588"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/121690.html" rel="external">"Society guideline links: Autism spectrum disorder"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Autism spectrum disorder (ASD) is a neurodevelopmental disorder with an incompletely understood etiology and no known cure. Many caregivers of children with ASD seek both conventional and complementary and alternative (CAM) therapies as part of the process of understanding and accepting the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is important to ask caregivers of children with ASD specifically about the use of CAM therapies and to work with them in a sensitive manner  (<a class="graphic graphic_table graphicRef57149" href="/d/graphic/57149.html" rel="external">table 2</a>). (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical practitioners play an essential role in helping caregivers evaluate information regarding CAM for children with ASD. It is important for clinicians to become knowledgeable about CAM therapies and to provide balanced information and advice about the potential benefits and risks. (See <a class="local">'Counseling caregivers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Few CAM therapies have been proven effective/ineffective or safe/unsafe in controlled trials  (<a class="graphic graphic_table graphicRef81572" href="/d/graphic/81572.html" rel="external">table 1</a>). Given the uncertainty, the clinician and family must weigh the unknown benefit against the potential risks, which include competition with validated treatment for time, effort, and financial resources. (See <a class="local">'Classification according to benefits and risks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12784" href="/d/drug information/12784.html" rel="external">Secretin</a> and facilitated communication are ineffective. We recommend <strong>not</strong> using secretin or facilitated communication for children with ASD (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Secretin'</a> above and <a class="local">'Facilitated communication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest <strong>not</strong> using a gluten-free casein-free diet for children with ASD who do not have celiac disease or gluten sensitivity (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Adherence to the diet is difficult and may be associated with nutritional deficiencies. (See <a class="local">'Gluten-free casein-free diet'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We strongly discourage CAM therapies with unknown benefits and potential risks in the treatment of ASD. These therapies include intravenous immunoglobulin, chelation, hyperbaric oxygen, antimicrobial agents, <a class="drug drug_pediatric" data-topicid="12753" href="/d/drug information/12753.html" rel="external">vitamin B6</a> and magnesium, vitamin A, homeopathy, vagus nerve stimulation, and stem cell transplantation  (<a class="graphic graphic_table graphicRef81572" href="/d/graphic/81572.html" rel="external">table 1</a>). (See <a class="local">'Unknown benefit, potential risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We do not actively encourage CAM therapies with possible/unknown benefit and low risk  (<a class="graphic graphic_table graphicRef81572" href="/d/graphic/81572.html" rel="external">table 1</a>) for our patients with ASD. Such therapies compete with validated therapies for time, effort, and financial resources. However, if families choose to use them, we monitor for side effects, interactions, and effects on prescribed/recommended therapies. (See <a class="local">'Possible benefit, low risk'</a> above and <a class="local">'Unknown benefit, low risk'</a> above.)</p><p></p><p class="headingAnchor" id="H3007151472"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Carolyn Bridgemohan, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">National Center for Complementary and Alternative Medicine. Expanding horizons of healthcare: five year strategic plan 2001-2005. US Department of Health and Human Services, Washington DC, 2000.</li><li><a class="nounderline abstract_t">Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2015; 24:117.</a></li><li><a class="nounderline abstract_t">Perrin JM, Coury DL, Hyman SL, et al. Complementary and alternative medicine use in a large pediatric autism sample. Pediatrics 2012; 130 Suppl 2:S77.</a></li><li><a class="nounderline abstract_t">Salomone E, Charman T, McConachie H, et al. Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe. Eur J Pediatr 2015; 174:1277.</a></li><li><a class="nounderline abstract_t">Owen-Smith AA, Bent S, Lynch FL, et al. Prevalence and Predictors of Complementary and Alternative Medicine Use in a Large Insured Sample of Children with Autism Spectrum Disorders. Res Autism Spectr Disord 2015; 17:40.</a></li><li><a class="nounderline abstract_t">Trudeau MS, Madden RF, Parnell JA, et al. Dietary and Supplement-Based Complementary and Alternative Medicine Use in Pediatric Autism Spectrum Disorder. Nutrients 2019; 11.</a></li><li><a class="nounderline abstract_t">Akins RS, Krakowiak P, Angkustsiri K, et al. Utilization patterns of conventional and complementary/alternative treatments in children with autism spectrum disorders and developmental disabilities in a population-based study. J Dev Behav Pediatr 2014; 35:1.</a></li><li><a class="nounderline abstract_t">Valicenti-McDermott M, Burrows B, Bernstein L, et al. Use of complementary and alternative medicine in children with autism and other developmental disabilities: associations with ethnicity, child comorbid symptoms, and parental stress. J Child Neurol 2014; 29:360.</a></li><li><a class="nounderline abstract_t">Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. Child Adolesc Psychiatr Clin N Am 2008; 17:803.</a></li><li><a class="nounderline abstract_t">Klein N, Kemper KJ. Integrative Approaches to Caring for Children with Autism. Curr Probl Pediatr Adolesc Health Care 2016; 46:195.</a></li><li><a class="nounderline abstract_t">Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord 2007; 37:628.</a></li><li><a class="nounderline abstract_t">Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. Pediatr Clin North Am 2007; 54:983.</a></li><li><a class="nounderline abstract_t">Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem 2009; 42:1032.</a></li><li><a class="nounderline abstract_t">James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 2004; 80:1611.</a></li><li><a class="nounderline abstract_t">Giulivi C, Zhang YF, Omanska-Klusek A, et al. Mitochondrial dysfunction in autism. JAMA 2010; 304:2389.</a></li><li><a class="nounderline abstract_t">Mitchell RH, Goldstein BI. Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review. J Am Acad Child Adolesc Psychiatry 2014; 53:274.</a></li><li><a class="nounderline abstract_t">Kazdin AE. Evidence-based assessment for children and adolescents: issues in measurement development and clinical application. J Clin Child Adolesc Psychol 2005; 34:548.</a></li><li><a class="nounderline abstract_t">Lilienfeld SO. Scientifically unsupported and supported interventions for childhood psychopathology: a summary. Pediatrics 2005; 115:761.</a></li><li><a class="nounderline abstract_t">Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. 1996. Clin Orthop Relat Res 2007; 455:3.</a></li><li><a class="nounderline abstract_t">Lord C, Charman T, Havdahl A, et al. The Lancet Commission on the future of care and clinical research in autism. Lancet 2022; 399:271.</a></li><li><a class="nounderline abstract_t">Golnik AE, Ireland M. Complementary alternative medicine for children with autism: a physician survey. J Autism Dev Disord 2009; 39:996.</a></li><li><a class="nounderline abstract_t">Lindly O, Thorburn S, Zuckerman K. Use and Nondisclosure of Complementary Health Approaches Among US Children with Developmental Disabilities. J Dev Behav Pediatr 2018; 39:217.</a></li><li><a class="nounderline abstract_t">Barbaresi WJ, Katusic SK, Voigt RG. Autism: a review of the state of the science for pediatric primary health care clinicians. Arch Pediatr Adolesc Med 2006; 160:1167.</a></li><li><a class="nounderline abstract_t">Sandler A. Placebo effects in developmental disabilities: implications for research and practice. Ment Retard Dev Disabil Res Rev 2005; 11:164.</a></li><li><a class="nounderline abstract_t">Kaptchuk TJ, Eisenberg DM. The persuasive appeal of alternative medicine. Ann Intern Med 1998; 129:1061.</a></li><li><a class="nounderline abstract_t">Hyman SL, Levy SE, Myers SM, COUNCIL ON CHILDREN WITH DISABILITIES, SECTION ON DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS. Identification, Evaluation, and Management of Children With Autism Spectrum Disorder. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Green VA, Pituch KA, Itchon J, et al. Internet survey of treatments used by parents of children with autism. Res Dev Disabil 2006; 27:70.</a></li><li><a class="nounderline abstract_t">Bowling A, Slavet J, Miller DP, et al. Cybercycling Effects on Classroom Behavior in Children With Behavioral Health Disorders: An RCT. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Saad K, Abdel-Rahman AA, Elserogy YM, et al. Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children. Nutr Neurosci 2016; 19:346.</a></li><li><a class="nounderline abstract_t">Kerley CP, Power C, Gallagher L, Coghlan D. Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT. Arch Dis Child 2017; 102:1030.</a></li><li class="breakAll">National Institute for Health and Care Excellence. Autism - management of autism in children and young people (CG170) http://guidance.nice.org.uk/CG170 (Accessed on September 05, 2013).</li><li class="breakAll">Scottish Intercollegiate Guidelines Network. Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Scottish Intercollegiate Guidelines Network, Edinburgh 2007. www.sign.ac.uk/guidelines/fulltext/98/index.html (Accessed on November 10, 2011).</li><li><a class="nounderline abstract_t">Maglione MA, Gans D, Das L, et al. Nonmedical interventions for children with ASD: recommended guidelines and further research needs. Pediatrics 2012; 130 Suppl 2:S169.</a></li><li><a class="nounderline abstract_t">Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; :CD003495.</a></li><li><a class="nounderline abstract_t">Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9:9.</a></li><li><a class="nounderline abstract_t">Kushak RI, Buie TM, Murray KF, et al. Evaluation of Intestinal Function in Children With Autism and Gastrointestinal Symptoms. J Pediatr Gastroenterol Nutr 2016; 62:687.</a></li><li><a class="nounderline abstract_t">Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005; 11:131.</a></li><li><a class="nounderline abstract_t">Mostert MP. Facilitated communication since 1995: a review of published studies. J Autism Dev Disord 2001; 31:287.</a></li><li><a class="nounderline abstract_t">Smith MD, Haas PJ, Belcher RG. Facilitated communication: the effects of facilitator knowledge and level of assistance on output. J Autism Dev Disord 1994; 24:357.</a></li><li><a class="nounderline abstract_t">Sathe N, Andrews JC, McPheeters ML, Warren ZE. Nutritional and Dietary Interventions for Autism Spectrum Disorder: A Systematic Review. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Marí-Bauset S, Zazpe I, Mari-Sanchis A, et al. Evidence of the gluten-free and casein-free diet in autism spectrum disorders: a systematic review. J Child Neurol 2014; 29:1718.</a></li><li><a class="nounderline abstract_t">Pavone L, Fiumara A, Bottaro G, et al. Autism and celiac disease: failure to validate the hypothesis that a link might exist. Biol Psychiatry 1997; 42:72.</a></li><li><a class="nounderline abstract_t">Black C, Kaye JA, Jick H. Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database. BMJ 2002; 325:419.</a></li><li><a class="nounderline abstract_t">Hunter LC, O'Hare A, Herron WJ, et al. Opioid peptides and dipeptidyl peptidase in autism. Dev Med Child Neurol 2003; 45:121.</a></li><li><a class="nounderline abstract_t">Le Couteur A, Trygstad O, Evered C, et al. Infantile autism and urinary excretion of peptides and protein-associated peptide complexes. J Autism Dev Disord 1988; 18:181.</a></li><li><a class="nounderline abstract_t">Buie T. The relationship of autism and gluten. Clin Ther 2013; 35:578.</a></li><li><a class="nounderline abstract_t">Keller A, Rimestad ML, Friis Rohde J, et al. The Effect of a Combined Gluten- and Casein-Free Diet on Children and Adolescents with Autism Spectrum Disorders: A Systematic Review and Meta-Analysis. Nutrients 2021; 13.</a></li><li><a class="nounderline abstract_t">Piwowarczyk A, Horvath A, Pisula E, et al. Gluten-Free Diet in Children with Autism Spectrum Disorders: A Randomized, Controlled, Single-Blinded Trial. J Autism Dev Disord 2020; 50:482.</a></li><li><a class="nounderline abstract_t">Gupta S. Immunological treatments for autism. J Autism Dev Disord 2000; 30:475.</a></li><li><a class="nounderline abstract_t">Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev 2007; 21:S57.</a></li><li><a class="nounderline abstract_t">Krause I, He XS, Gershwin ME, Shoenfeld Y. Brief report: immune factors in autism: a critical review. J Autism Dev Disord 2002; 32:337.</a></li><li><a class="nounderline abstract_t">Gupta S, Aggarwal S, Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 1996; 26:439.</a></li><li><a class="nounderline abstract_t">Connery K, Tippett M, Delhey LM, et al. Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism. Transl Psychiatry 2018; 8:148.</a></li><li><a class="nounderline abstract_t">Melamed IR, Heffron M, Testori A, Lipe K. A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation. Autism Res 2018; 11:421.</a></li><li><a class="nounderline abstract_t">DelGiudice-Asch G, Simon L, Schmeidler J, et al. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord 1999; 29:157.</a></li><li><a class="nounderline abstract_t">Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol 1998; 13:79.</a></li><li><a class="nounderline abstract_t">Niederhofer H, Staffen W, Mair A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology 2003; 28:1014.</a></li><li><a class="nounderline abstract_t">Lagan NC, Balfe J. Question 2: Does heavy metal chelation therapy improve the symptoms of autism spectrum disorder. Arch Dis Child 2018; 103:910.</a></li><li><a class="nounderline abstract_t">Voelker R. FDA warning targets OTC chelation products. JAMA 2010; 304:2112.</a></li><li class="breakAll">US Food and Drug Administration. Chelation products: Unapproved over-the-counter drugs -- consumer warning. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm229454.htm.</li><li><a class="nounderline abstract_t">Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results. BMC Clin Pharmacol 2009; 9:17.</a></li><li><a class="nounderline abstract_t">Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results. BMC Clin Pharmacol 2009; 9:16.</a></li><li><a class="nounderline abstract_t">James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev 2015; :CD010766.</a></li><li><a class="nounderline abstract_t">Baxter AJ, Krenzelok EP. Pediatric fatality secondary to EDTA chelation. Clin Toxicol (Phila) 2008; 46:1083.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55:204.</a></li><li><a class="nounderline abstract_t">Rossignol DA. Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism. Med Hypotheses 2007; 68:1208.</a></li><li><a class="nounderline abstract_t">Xiong T, Chen H, Luo R, Mu D. Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). Cochrane Database Syst Rev 2016; 10:CD010922.</a></li><li><a class="nounderline abstract_t">Podgórska-Bednarz J, Perenc L. Hyperbaric Oxygen Therapy for Children and Youth with Autism Spectrum Disorder: A Review. Brain Sci 2021; 11.</a></li><li><a class="nounderline abstract_t">Shaw W, Kassen E, Chaves E. Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features. Clin Chem 1995; 41:1094.</a></li><li><a class="nounderline abstract_t">Pardo CA, Buckley A, Thurm A, et al. A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord 2013; 5:9.</a></li><li><a class="nounderline abstract_t">Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 2005; :CD003497.</a></li><li><a class="nounderline abstract_t">Murza KA, Pavelko SL, Malani MD, Nye C. Vitamin B6-magnesium treatment for autism: the current status of the research. Magnes Res 2010; 23:115.</a></li><li><a class="nounderline abstract_t">Aviner S, Berkovitch M, Dalkian H, et al. Use of a homeopathic preparation for "infantile colic" and an apparent life-threatening event. Pediatrics 2010; 125:e318.</a></li><li><a class="nounderline abstract_t">Dawson G, Sun JM, Baker J, et al. A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder. J Pediatr 2020; 222:164.</a></li><li><a class="nounderline abstract_t">Ardhanareeswaran K, Coppola G, Vaccarino F. The use of stem cells to study autism spectrum disorder. Yale J Biol Med 2015; 88:5.</a></li><li><a class="nounderline abstract_t">Mohammadi D. The dangers of unregulated stem-cell marketing. Lancet 2017; 390:1823.</a></li><li><a class="nounderline abstract_t">Hartnett KP, Powell KM, Rankin D, et al. Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies. JAMA Netw Open 2021; 4:e2128615.</a></li><li><a class="nounderline abstract_t">Brondino N, Fusar-Poli L, Rocchetti M, et al. Complementary and Alternative Therapies for Autism Spectrum Disorder. Evid Based Complement Alternat Med 2015; 2015:258589.</a></li><li><a class="nounderline abstract_t">Weitlauf AS, Sathe N, McPheeters ML, Warren ZE. Interventions Targeting Sensory Challenges in Autism Spectrum Disorder: A Systematic Review. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Geretsegger M, Fusar-Poli L, Elefant C, et al. Music therapy for autistic people. Cochrane Database Syst Rev 2022; 5:CD004381.</a></li><li><a class="nounderline abstract_t">Bass MM, Duchowny CA, Llabre MM. The effect of therapeutic horseback riding on social functioning in children with autism. J Autism Dev Disord 2009; 39:1261.</a></li><li><a class="nounderline abstract_t">Gabriels RL, Pan Z, Dechant B, et al. Randomized Controlled Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder. J Am Acad Child Adolesc Psychiatry 2015; 54:541.</a></li><li><a class="nounderline abstract_t">Borgi M, Loliva D, Cerino S, et al. Effectiveness of a Standardized Equine-Assisted Therapy Program for Children with Autism Spectrum Disorder. J Autism Dev Disord 2016; 46:1.</a></li><li><a class="nounderline abstract_t">Hoagwood KE, Acri M, Morrissey M, Peth-Pierce R. Animal-Assisted Therapies for Youth with or at risk for Mental Health Problems: A Systematic Review. Appl Dev Sci 2017; 21:1.</a></li><li><a class="nounderline abstract_t">Zhao M, Chen S, You Y, et al. Effects of a Therapeutic Horseback Riding Program on Social Interaction and Communication in Children with Autism. Int J Environ Res Public Health 2021; 18.</a></li><li><a class="nounderline abstract_t">O'Haire ME, McKenzie SJ, Beck AM, Slaughter V. Animals may act as social buffers: Skin conductance arousal in children with autism spectrum disorder in a social context. Dev Psychobiol 2015; 57:584.</a></li><li><a class="nounderline abstract_t">O'Haire ME, McKenzie SJ, Beck AM, Slaughter V. Social behaviors increase in children with autism in the presence of animals compared to toys. PLoS One 2013; 8:e57010.</a></li><li><a class="nounderline abstract_t">Charry-Sánchez JD, Pradilla I, Talero-Gutiérrez C. Effectiveness of Animal-Assisted Therapy in the Pediatric Population: Systematic Review and Meta-Analysis of Controlled Studies. J Dev Behav Pediatr 2018; 39:580.</a></li><li><a class="nounderline abstract_t">Hill J, Ziviani J, Driscoll C, et al. Canine Assisted Occupational Therapy for Children on the Autism Spectrum: A Pilot Randomised Control Trial. J Autism Dev Disord 2020; 50:4106.</a></li><li><a class="nounderline abstract_t">Zhang Y, Kensler TW, Cho CG, et al. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci U S A 1994; 91:3147.</a></li><li><a class="nounderline abstract_t">Zhang Y, Talalay P, Cho CG, Posner GH. A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A 1992; 89:2399.</a></li><li><a class="nounderline abstract_t">Singh K, Connors SL, Macklin EA, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci U S A 2014; 111:15550.</a></li><li><a class="nounderline abstract_t">Zimmerman AW, Singh K, Connors SL, et al. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism 2021; 12:38.</a></li><li class="breakAll">Autism Speaks. Broccoli sprouts for autism? What you need to know. http://www.autismspeaks.org/blog/2014/10/14/broccoli-sprouts-autism-what-you-need-know (Accessed on February 05, 2015).</li><li><a class="nounderline abstract_t">Oberman LM, Enticott PG, Casanova MF, et al. Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research. Autism Res 2016; 9:184.</a></li><li><a class="nounderline abstract_t">Sokhadze EM, El-Baz A, Baruth J, et al. Effects of low frequency repetitive transcranial magnetic stimulation (rTMS) on gamma frequency oscillations and event-related potentials during processing of illusory figures in autism. J Autism Dev Disord 2009; 39:619.</a></li><li><a class="nounderline abstract_t">Garvey MA, Gilbert DL. Transcranial magnetic stimulation in children. Eur J Paediatr Neurol 2004; 8:7.</a></li><li><a class="nounderline abstract_t">Rajapakse T, Kirton A. NON-INVASIVE BRAIN STIMULATION IN CHILDREN: APPLICATIONS AND FUTURE DIRECTIONS. Transl Neurosci 2013; 4.</a></li><li><a class="nounderline abstract_t">Rossi S, Hallett M, Rossini PM, et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 2009; 120:2008.</a></li><li><a class="nounderline abstract_t">SECTION ON INTEGRATIVE MEDICINE. Mind-Body Therapies in Children and Youth. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Koenig KP, Buckley-Reen A, Garg S. Efficacy of the Get Ready to Learn yoga program among children with autism spectrum disorders: a pretest-posttest control group design. Am J Occup Ther 2012; 66:538.</a></li><li><a class="nounderline abstract_t">Rosenblatt LE, Gorantla S, Torres JA, et al. Relaxation response-based yoga improves functioning in young children with autism: a pilot study. J Altern Complement Med 2011; 17:1029.</a></li><li><a class="nounderline abstract_t">Hourston S, Atchley R. Autism and Mind-Body Therapies: A Systematic Review. J Altern Complement Med 2017; 23:331.</a></li><li><a class="nounderline abstract_t">Silva LM, Schalock M, Ayres R, et al. Qigong massage treatment for sensory and self-regulation problems in young children with autism: a randomized controlled trial. Am J Occup Ther 2009; 63:423.</a></li><li><a class="nounderline abstract_t">Silva LM, Cignolini A, Warren R, et al. Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology. Am J Chin Med 2007; 35:393.</a></li><li><a class="nounderline abstract_t">Lee MS, Kim JI, Ernst E. Massage therapy for children with autism spectrum disorders: a systematic review. J Clin Psychiatry 2011; 72:406.</a></li><li><a class="nounderline abstract_t">Holtmann M, Steiner S, Hohmann S, et al. Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 2011; 53:986.</a></li><li><a class="nounderline abstract_t">Hurt E, Arnold LE, Lofthouse N. Quantitative EEG neurofeedback for the treatment of pediatric attention-deficit/hyperactivity disorder, autism spectrum disorders, learning disorders, and epilepsy. Child Adolesc Psychiatr Clin N Am 2014; 23:465.</a></li><li><a class="nounderline abstract_t">Bertoglio K, Jill James S, Deprey L, et al. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med 2010; 16:555.</a></li><li><a class="nounderline abstract_t">Hendren RL, James SJ, Widjaja F, et al. Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism. J Child Adolesc Psychopharmacol 2016; 26:774.</a></li><li><a class="nounderline abstract_t">Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry 2018; 23:247.</a></li><li><a class="nounderline abstract_t">Frye RE, Melnyk S, Fuchs G, et al. Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat 2013; 2013:609705.</a></li><li><a class="nounderline abstract_t">Sun C, Zou M, Zhao D, et al. Efficacy of Folic Acid Supplementation in Autistic Children Participating in Structured Teaching: An Open-Label Trial. Nutrients 2016; 8.</a></li><li><a class="nounderline abstract_t">Sinha Y, Silove N, Hayen A, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011; :CD003681.</a></li><li><a class="nounderline abstract_t">Sliwinski S, Croonenberghs J, Christophe A, et al. Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism? Neuro Endocrinol Lett 2006; 27:465.</a></li><li><a class="nounderline abstract_t">Vancassel S, Durand G, Barthélémy C, et al. Plasma fatty acid levels in autistic children. Prostaglandins Leukot Essent Fatty Acids 2001; 65:1.</a></li><li><a class="nounderline abstract_t">Parletta N, Niyonsenga T, Duff J. Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls. PLoS One 2016; 11:e0156432.</a></li><li><a class="nounderline abstract_t">Bent S, Bertoglio K, Hendren RL. Omega-3 fatty acids for autistic spectrum disorder: a systematic review. J Autism Dev Disord 2009; 39:1145.</a></li><li><a class="nounderline abstract_t">James S, Montgomery P, Williams K. Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2011; :CD007992.</a></li><li class="breakAll">Newberry SJ, Chung M, Booth, M et al. Omega-3 fatty acids and maternal and child health: An updated systematic review. Evidence Report/Technology Assessment No. 224. AHRQ Publication No. 16-E003-EF. Rockville, MD, 2016. http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&amp;productid=2321 (Accessed on October 26, 2016).</li><li><a class="nounderline abstract_t">Fraguas D, Díaz-Caneja CM, Pina-Camacho L, et al. Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis. Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Weitlauf AS, Goode RH, Warren Z. Do We Have Evidence for Dietary and Nutritional Interventions for Autism Spectrum Disorder? Pediatrics 2019; 144.</a></li><li><a class="nounderline abstract_t">Amminger GP, Berger GE, Schäfer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007; 61:551.</a></li><li><a class="nounderline abstract_t">Bent S, Bertoglio K, Ashwood P, et al. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord 2011; 41:545.</a></li><li><a class="nounderline abstract_t">Degnan FH. The US Food and Drug Administration and probiotics: regulatory categorization. Clin Infect Dis 2008; 46 Suppl 2:S133.</a></li><li><a class="nounderline abstract_t">Lewis ZT, Shani G, Masarweh CF, et al. Validating bifidobacterial species and subspecies identity in commercial probiotic products. Pediatr Res 2016; 79:445.</a></li><li><a class="nounderline abstract_t">Yap CX, Henders AK, Alvares GA, et al. Autism-related dietary preferences mediate autism-gut microbiome associations. Cell 2021; 184:5916.</a></li><li><a class="nounderline abstract_t">Ng QX, Loke W, Venkatanarayanan N, et al. A Systematic Review of the Role of Prebiotics and Probiotics in Autism Spectrum Disorders. Medicina (Kaunas) 2019; 55.</a></li><li><a class="nounderline abstract_t">Hadland SE, Knight JR, Harris SK. Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice. J Dev Behav Pediatr 2015; 36:115.</a></li><li><a class="nounderline abstract_t">Campbell CT, Phillips MS, Manasco K. Cannabinoids in Pediatrics. J Pediatr Pharmacol Ther 2017; 22:176.</a></li><li><a class="nounderline abstract_t">Zhang L, Alger BE. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J Neurosci 2010; 30:5724.</a></li><li><a class="nounderline abstract_t">Aran A, Harel M, Cassuto H, et al. Cannabinoid treatment for autism: a proof-of-concept randomized trial. Mol Autism 2021; 12:6.</a></li><li class="breakAll">Cannabidivarin (CBDV) vs. placebo in children with autism spectrum disorder (ASD). US National Library of Medicine ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03202303 (Accessed on July 18, 2018).</li><li class="breakAll">Cannabinoids for behavioral problems in children With ASD (CBA). US National Library of Medicine ClinicalTrials.gov. Available at: https://www.clinicaltrials.gov/ct2/show/NCT02956226 (Accessed on July 18, 2018).</li><li class="breakAll">Cannabidiol for ASD open trial. US National Library of Medicine ClinicalTrials.gov. Available at: https://www.clinicaltrials.gov/ct2/show/NCT03900923 (Accessed on November 17, 2019).</li><li><a class="nounderline abstract_t">Kurz R, Blass K. Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child. Cannabinoids 2010; 5:4.</a></li><li><a class="nounderline abstract_t">Aran A, Cassuto H, Lubotzky A, et al. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study. J Autism Dev Disord 2019; 49:1284.</a></li><li><a class="nounderline abstract_t">Bar-Lev Schleider L, Mechoulam R, Saban N, et al. Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy. Sci Rep 2019; 9:200.</a></li><li><a class="nounderline abstract_t">Barchel D, Stolar O, De-Haan T, et al. Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities. Front Pharmacol 2018; 9:1521.</a></li><li><a class="nounderline abstract_t">Agarwal R, Burke SL, Maddux M. Current state of evidence of cannabis utilization for treatment of autism spectrum disorders. BMC Psychiatry 2019; 19:328.</a></li><li><a class="nounderline abstract_t">Devinsky O, Patel AD, Cross JH, et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. N Engl J Med 2018; 378:1888.</a></li><li><a class="nounderline abstract_t">Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2018; 391:1085.</a></li><li><a class="nounderline abstract_t">Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017; 376:2011.</a></li><li><a class="nounderline abstract_t">Hardan AY, Fung LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 2012; 71:956.</a></li><li><a class="nounderline abstract_t">Main PA, Angley MT, Thomas P, et al. Folate and methionine metabolism in autism: a systematic review. Am J Clin Nutr 2010; 91:1598.</a></li><li><a class="nounderline abstract_t">Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:765.</a></li><li><a class="nounderline abstract_t">Kern JK, Miller VS, Cauller PL, et al. Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. J Child Neurol 2001; 16:169.</a></li><li><a class="nounderline abstract_t">Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord 1999; 29:191.</a></li><li><a class="nounderline abstract_t">Saad K, Eltayeb AA, Mohamad IL, et al. A Randomized, Placebo-controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders. Clin Psychopharmacol Neurosci 2015; 13:188.</a></li><li><a class="nounderline abstract_t">Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. J Autism Dev Disord 2010; 40:1131.</a></li><li><a class="nounderline abstract_t">Rayan A, Ahmad M. Effectiveness of mindfulness-based interventions on quality of life and positive reappraisal coping among parents of children with autism spectrum disorder. Res Dev Disabil 2016; 55:185.</a></li><li><a class="nounderline abstract_t">Lunsky Y, P Hastings R, Weiss JA, et al. Comparative Effects of Mindfulness and Support and Information Group Interventions for Parents of Adults with Autism Spectrum Disorder and Other Developmental Disabilities. J Autism Dev Disord 2017; 47:1769.</a></li><li><a class="nounderline abstract_t">de Bruin EI, Blom R, Smit FM, et al. MYmind: Mindfulness training for Youngsters with autism spectrum disorders and their parents. Autism 2015; 19:906.</a></li><li><a class="nounderline abstract_t">Bluth K, Roberson PN, Billen RM, Sams JM. A Stress Model for Couples Parenting Children With Autism Spectrum Disorders and the Introduction of a Mindfulness Intervention. J Fam Theory Rev 2013; 5:194.</a></li><li><a class="nounderline abstract_t">Singh NN, Lancioni GE, Manikam R, et al. A mindfulness-based strategy for self-management of aggressive behavior in adolescents with autism. Res Autism Spectr Disord 2011; 5:1153.</a></li><li><a class="nounderline abstract_t">Hwang YS, Kearney P, Klieve H, et al. Cultivating mind: Mindfulness interventions for children with autism spectrum disorders and problem behaviours, and their mothers. J Child Fam Stud 2015; 24:3093.</a></li><li><a class="nounderline abstract_t">Keenan-Mount R, Albrecht NJ, Waters L. Mindfulness-based approaches for young people with autism spectrum disorder and their caregivers: Do these approaches hold benefits for teachers? Australian Journal of Teacher Education 2016; 41:68.</a></li><li><a class="nounderline abstract_t">Lee MS, Choi TY, Shin BC, Ernst E. Acupuncture for children with autism spectrum disorders: a systematic review of randomized clinical trials. J Autism Dev Disord 2012; 42:1671.</a></li><li><a class="nounderline abstract_t">Ming X, Chen X, Wang XT, et al. Acupuncture for treatment of autism spectrum disorders. Evid Based Complement Alternat Med 2012; 2012:679845.</a></li><li><a class="nounderline abstract_t">Adams D, Cheng F, Jou H, et al. The safety of pediatric acupuncture: a systematic review. Pediatrics 2011; 128:e1575.</a></li><li><a class="nounderline abstract_t">Posadzki P, Lee MS, Ernst E. Osteopathic manipulative treatment for pediatric conditions: a systematic review. Pediatrics 2013; 132:140.</a></li><li><a class="nounderline abstract_t">Carbone PS, Farley M, Davis T. Primary care for children with autism. Am Fam Physician 2010; 81:453.</a></li></ol></div><div id="topicVersionRevision">Topic 605 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : National Center for Complementary and Alternative Medicine. Expanding horizons of healthcare: five year strategic plan 2001-2005. US Department of Health and Human Services, Washington DC, 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25455579" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Complementary and alternative medicine treatments for children with autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118257" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Complementary and alternative medicine use in a large pediatric autism sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855095" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and correlates of use of complementary and alternative medicine in children with autism spectrum disorder in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26366192" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prevalence and Predictors of Complementary and Alternative Medicine Use in a Large Insured Sample of Children with Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31375014" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Dietary and Supplement-Based Complementary and Alternative Medicine Use in Pediatric Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399100" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Utilization patterns of conventional and complementary/alternative treatments in children with autism spectrum disorders and developmental disabilities in a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23372032" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Use of complementary and alternative medicine in children with autism and other developmental disabilities: associations with ethnicity, child comorbid symptoms, and parental stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18775371" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Complementary and alternative medicine treatments for children with autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26776326" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Integrative Approaches to Caring for Children with Autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16977497" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061787" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19306862" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15585776" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21119085" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mitochondrial dysfunction in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24565356" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Inflammation in children and adolescents with neuropsychiatric disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16026218" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Evidence-based assessment for children and adolescents: issues in measurement development and clinical application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741383" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Scientifically unsupported and supported interventions for childhood psychopathology: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17340682" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Evidence based medicine: what it is and what it isn't. 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34883054" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Lancet Commission on the future of care and clinical research in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19280328" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Complementary alternative medicine for children with autism: a physician survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29570567" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use and Nondisclosure of Complementary Health Approaches Among US Children with Developmental Disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17088521" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Autism: a review of the state of the science for pediatric primary health care clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15977316" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Placebo effects in developmental disabilities: implications for research and practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9867762" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The persuasive appeal of alternative medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843864" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification, Evaluation, and Management of Children With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15919178" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Internet survey of treatments used by parents of children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28069663" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cybercycling Effects on Classroom Behavior in Children With Behavioral Health Disorders: An RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876214" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626020" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626020" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626020" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23118248" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nonmedical interventions for children with ASD: recommended guidelines and further research needs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513913" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Intravenous secretin for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585670" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved social and language skills after secretin administration in patients with autistic spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26913756" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Evaluation of Intestinal Function in Children With Autism and Gastrointestinal Symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15977319" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Novel treatments for autistic spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11518483" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Facilitated communication since 1995: a review of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8050988" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Facilitated communication: the effects of facilitator knowledge and level of assistance on output.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562286" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nutritional and Dietary Interventions for Autism Spectrum Disorder: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24789114" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Evidence of the gluten-free and casein-free diet in autism spectrum disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9193744" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autism and celiac disease: failure to validate the hypothesis that a link might exist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12193358" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Relation of childhood gastrointestinal disorders to autism: nested case-control study using data from the UK General Practice Research Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12578238" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Opioid peptides and dipeptidyl peptidase in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3410809" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Infantile autism and urinary excretion of peptides and protein-associated peptide complexes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23688532" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The relationship of autism and gluten.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33573238" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The Effect of a Combined Gluten- and Casein-Free Diet on Children and Adolescents with Autism Spectrum Disorders: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31659595" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gluten-Free Diet in Children with Autism Spectrum Disorders: A Randomized, Controlled, Single-Blinded Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11098887" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Immunological treatments for autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397768" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Guidelines on the use of intravenous immune globulin for neurologic conditions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12199139" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Brief report: immune factors in autism: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8863094" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30097568" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Intravenous immunoglobulin for the treatment of autoimmune encephalopathy in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29427532" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A pilot study of high-dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10382136" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9512308" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intravenous immunoglobulin treatment of children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700706" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30007948" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Question 2: Does heavy metal chelation therapy improve the symptoms of autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081718" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : FDA warning targets OTC chelation products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21081718" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : FDA warning targets OTC chelation products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19852790" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19852789" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26106752" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Chelation for autism spectrum disorder (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18949650" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pediatric fatality secondary to EDTA chelation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511441" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17141962" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hyperbaric oxygen therapy might improve certain pathophysiological findings in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737490" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34356150" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hyperbaric Oxygen Therapy for Children and Youth with Autism Spectrum Disorder: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7628083" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Increased urinary excretion of analogs of Krebs cycle metabolites and arabinose in two brothers with autistic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23566357" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A pilot open-label trial of minocycline in patients with autism and regressive features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16235322" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Combined vitamin B6-magnesium treatment in autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20562088" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Vitamin B6-magnesium treatment for autism: the current status of the research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100745" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Use of a homeopathic preparation for "infantile colic" and an apparent life-threatening event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32444220" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25745370" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The use of stem cells to study autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28870714" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The dangers of unregulated stem-cell marketing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34618037" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26064157" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Complementary and Alternative Therapies for Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28562287" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Interventions Targeting Sensory Challenges in Autism Spectrum Disorder: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35532041" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Music therapy for autistic people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19350376" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The effect of therapeutic horseback riding on social functioning in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26088658" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized Controlled Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26210515" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Effectiveness of a Standardized Equine-Assisted Therapy Program for Children with Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28798541" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Animal-Assisted Therapies for Youth with or at risk for Mental Health Problems: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33800787" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Effects of a Therapeutic Horseback Riding Program on Social Interaction and Communication in Children with Autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913902" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Animals may act as social buffers: Skin conductance arousal in children with autism spectrum disorder in a social context.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23468902" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Social behaviors increase in children with autism in the presence of animals compared to toys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29994814" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effectiveness of Animal-Assisted Therapy in the Pediatric Population: Systematic Review and Meta-Analysis of Controlled Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266682" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Canine Assisted Occupational Therapy for Children on the Autism Spectrum: A Pilot Randomised Control Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8159717" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1549603" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25313065" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Sulforaphane treatment of autism spectrum disorder (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34034808" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34034808" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26536383" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Transcranial magnetic stimulation in autism spectrum disorder: Challenges, promise, and roadmap for future research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19030976" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Effects of low frequency repetitive transcranial magnetic stimulation (rTMS) on gamma frequency oscillations and event-related potentials during processing of illusory figures in autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15023371" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Transcranial magnetic stimulation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24163755" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : NON-INVASIVE BRAIN STIMULATION IN CHILDREN: APPLICATIONS AND FUTURE DIRECTIONS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19833552" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27550982" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Mind-Body Therapies in Children and Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917120" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Efficacy of the Get Ready to Learn yoga program among children with autism spectrum disorders: a pretest-posttest control group design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21992466" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Relaxation response-based yoga improves functioning in young children with autism: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28437148" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Autism and Mind-Body Therapies: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19708471" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Qigong massage treatment for sensory and self-regulation problems in young children with autism: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597498" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Improvement in sensory impairment and social interaction in young children with autism following treatment with an original Qigong massage methodology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208598" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Massage therapy for children with autism spectrum disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21752020" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Neurofeedback in autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975622" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Quantitative EEG neurofeedback for the treatment of pediatric attention-deficit/hyperactivity disorder, autism spectrum disorders, learning disorders, and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804367" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26889605" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Randomized, Placebo-Controlled Trial of Methyl B12 for Children with Autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27752075" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24224089" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effectiveness of methylcobalamin and folinic Acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27338456" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Efficacy of Folic Acid Supplementation in Autistic Children Participating in Structured Teaching: An Open-Label Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161380" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Auditory integration training and other sound therapies for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16891996" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Polyunsaturated fatty acids: do they have a role in the pathophysiology of autism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11487301" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Plasma fatty acid levels in autistic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27232999" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Omega-3 and Omega-6 Polyunsaturated Fatty Acid Levels and Correlations with Symptoms in Children with Attention Deficit Hyperactivity Disorder, Autistic Spectrum Disorder and Typically Developing Controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19333748" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Omega-3 fatty acids for autistic spectrum disorder: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071839" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Omega-3 fatty acids supplementation for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071839" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Omega-3 fatty acids supplementation for autism spectrum disorders (ASD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586029" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Dietary Interventions for Autism Spectrum Disorder: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586030" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Do We Have Evidence for Dietary and Nutritional Interventions for Autism Spectrum Disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16920077" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20683766" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18181719" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The US Food and Drug Administration and probiotics: regulatory categorization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571226" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Validating bifidobacterial species and subspecies identity in commercial probiotic products.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34767757" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Autism-related dietary preferences mediate autism-gut microbiome associations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31083360" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A Systematic Review of the Role of Prebiotics and Probiotics in Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25650954" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Medical marijuana: review of the science and implications for developmental-behavioral pediatric practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28638299" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Cannabinoids in Pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410124" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33536055" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Cannabinoid treatment for autism: a proof-of-concept randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33536055" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cannabinoid treatment for autism: a proof-of-concept randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33536055" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Cannabinoid treatment for autism: a proof-of-concept randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33536055" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cannabinoid treatment for autism: a proof-of-concept randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30382443" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30655581" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Real life Experience of Medical Cannabis Treatment in Autism: Analysis of Safety and Efficacy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30687090" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31664964" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Current state of evidence of cannabis utilization for treatment of autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29768152" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29395273" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538134" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22342106" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410097" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Folate and methionine metabolism in autism: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8255984" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : A preliminary trial of ascorbic acid as supplemental therapy for autism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11305684" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10425581" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26243847" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : A Randomized, Placebo-controlled Trial of Digestive Enzymes in Children with Autism Spectrum Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20204691" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107368" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Effectiveness of mindfulness-based interventions on quality of life and positive reappraisal coping among parents of children with autism spectrum disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28374207" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Comparative Effects of Mindfulness and Support and Information Group Interventions for Parents of Adults with Autism Spectrum Disorder and Other Developmental Disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25348866" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : MYmind: Mindfulness training for Youngsters with autism spectrum disorders and their parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795780" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A Stress Model for Couples Parenting Children With Autism Spectrum Disorders and the Introduction of a Mindfulness Intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : A mindfulness-based strategy for self-management of aggressive behavior in adolescents with autism</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Cultivating mind: Mindfulness interventions for children with autism spectrum disorders and problem behaviours, and their mothers</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Mindfulness-based approaches for young people with autism spectrum disorder and their caregivers: Do these approaches hold benefits for teachers?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22124580" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Acupuncture for children with autism spectrum disorders: a systematic review of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22203876" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Acupuncture for treatment of autism spectrum disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22106073" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : The safety of pediatric acupuncture: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23776117" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Osteopathic manipulative treatment for pediatric conditions: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20148499" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Primary care for children with autism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
